1-20 of 50
David S. Hong
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Impact of Co-mutations and Transcriptional Signatures in Non–Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial

Marcelo V. Negrao, Alvaro G. Paula, David Molkentine, Laura Hover, Monique Nilsson, Natalie Vokes, Lars Engstrom, Andrew Calinisan, David M. Briere, Laura Waters, Jill Hallin, Lixia Diao, Mehmet Altan, George R. Blumenschein, Ferdinandos Skoulidis, Jing Wang, Scott E. Kopetz, David S. Hong, Don L. Gibbons, Peter Olson, James G. Christensen, John V. Heymach
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (6): 1069–1081.
https://doi.org/10.1158/1078-0432.CCR-24-2310
Published: 17 March 2025
View articletitled, Impact of Co-mutations and Transcriptional Signatures in Non–Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial
Open the PDF for Impact of Co-mutations and Transcriptional Signatures in Non–Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial in another window
Includes: Supplementary data
Journal Articles

Clinical and Genomic Landscape of RAS Mutations in Gynecologic Cancers

Ji Son, Yingao Zhang, Heather Lin, Oriol Mirallas, Pablo Alvarez Ballesteros, Mirella Nardo, Natalie Clark, R. Tyler Hillman, Erick Campbell, Vijaykumar Holla, Amber M. Johnson, Amadeo B. Biter, Ying Yuan, Lauren P. Cobb, David M. Gershenson, Amir A. Jazaeri, Karen H. Lu, Pamela T. Soliman, Shannon N. Westin, Elizabeth D. Euscher, Barrett C. Lawson, Richard K. Yang, Funda Meric-Bernstam, David S. Hong
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (14): 2986–2995.
https://doi.org/10.1158/1078-0432.CCR-23-2819
Published: 15 July 2024
View articletitled, Clinical and Genomic Landscape of RAS Mutations in Gynecologic Cancers
Open the PDF for Clinical and Genomic Landscape of RAS Mutations in Gynecologic Cancers in another window
Includes: Supplementary data
Journal Articles

Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial

David S. Hong, Michael Postow, Bartosz Chmielowski, Ryan Sullivan, Amita Patnaik, Ezra E.W. Cohen, Geoffrey Shapiro, Conor Steuer, Martin Gutierrez, Heather Yeckes-Rodin, Robert Ilaria, Jr, Brenda O'Connell, Joanna Peng, Guangbin Peng, Nora Zizlsperger, Anthony Tolcher, Jedd D. Wolchok
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (12): 2210–2219.
https://doi.org/10.1158/1078-0432.CCR-22-3313
Published: 13 June 2023
View articletitled, Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial
Open the PDF for Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial in another window
Includes: Supplementary data
Journal Articles

Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101)

Roberto Carmagnani Pestana, Justin T. Moyers, Jason Roszik, Shiraj Sen, David S. Hong, Aung Naing, Cynthia E. Herzog, Siqing Fu, Sarina A. Piha-Paul, Jordi Rodon, Timothy A. Yap, Daniel D. Karp, Apostolia M. Tsimberidou, Shubham Pant, Maria A. Zarzour, Ravin Ratan, Vinod Ravi, Robert S. Benjamin, Alexander J. Lazar, Wei-Lien Wang, Najat Daw, Jonathan B. Gill, Douglas J. Harrison, Valerae O. Lewis, Christina L. Roland, Shreyaskumar R. Patel, J. Andrew Livingston, Neeta Somaiah, Joseph A. Ludwig, Anthony P. Conley, Nelson Hamerschlak, Richard Gorlick, Funda Meric-Bernstam, Vivek Subbiah
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (9): 1708–1718.
https://doi.org/10.1158/1078-0432.CCR-22-3629
Published: 01 May 2023
View articletitled, Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101)
Open the PDF for Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101) in another window
Includes: Supplementary data
Journal Articles

Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102)

Justin T. Moyers, Roberto Carmagnani Pestana, Jason Roszik, David S. Hong, Aung Naing, Siqing Fu, Sarina Piha-Paul, Timothy A. Yap, Daniel Karp, Jordi Rodon, Andy Livingston, Maria Alejandra Zarzour, Vinod Ravi, Shreyaskumar Patel, Robert S. Benjamin, Joseph Ludwig, Cynthia Herzog, Ravin Ratan, Neeta Somaiah, Anthony Conley, Richard Gorlick, Funda Meric-Bernstam, Vivek Subbiah
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (2): 401–409.
https://doi.org/10.1158/1078-0432.CCR-22-2509
Published: 17 January 2023
View articletitled, Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102)
Open the PDF for Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102) in another window
Includes: Supplementary data
Journal Articles

Mogamulizumab in Combination with Nivolumab in a Phase I/II Study of Patients with Locally Advanced or Metastatic Solid Tumors

David S. Hong, Olivier Rixe, Vi K. Chiu, Patrick M. Forde, Tomislav Dragovich, Yanyan Lou, Asha Nayak-Kapoor, Rom Leidner, James N. Atkins, Agron Collaku, Floyd E. Fox, Margaret A. Marshall, Anthony J. Olszanski
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (3): 479–488.
https://doi.org/10.1158/1078-0432.CCR-21-2781
Published: 01 February 2022
View articletitled, Mogamulizumab in Combination with Nivolumab in a Phase I/II Study of Patients with Locally Advanced or Metastatic Solid Tumors
Open the PDF for Mogamulizumab in Combination with Nivolumab in a Phase I/II Study of Patients with Locally Advanced or Metastatic Solid Tumors in another window
Journal Articles

Correction: Phase I Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53

Mansoor N. Saleh, Manish R. Patel, Todd M. Bauer, Sanjay Goel, Gerald S. Falchook, Geoffrey I. Shapiro, Ki Y. Chung, Jeffrey R. Infante, Robert M. Conry, Guilherme Rabinowits, David S. Hong, Judy S. Wang, Ulrich Steidl, Loren D. Walensky, Gurudatta Naik, Vincent Guerlavais, Vojislav Vukovic, D. Allen Annis, Manuel Aivado, Funda Meric-Bernstam
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (2): 429.
https://doi.org/10.1158/1078-0432.CCR-21-4241
Published: 15 January 2022
View articletitled, Correction: Phase I Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53
Open the PDF for Correction: Phase I Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53 in another window
Journal Articles

Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody–Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non–Small Cell Lung Carcinoma

D. Ross Camidge, Daniel Morgensztern, Rebecca S. Heist, Minal Barve, Everett Vokes, Jonathan W. Goldman, David S. Hong, Todd M. Bauer, John H. Strickler, Eric Angevin, Monica Motwani, Apurvasena Parikh, Zhaowen Sun, Bruce Allen Bach, Jun Wu, Philip B. Komarnitsky, Karen Kelly
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (21): 5781–5792.
https://doi.org/10.1158/1078-0432.CCR-21-0765
Published: 01 November 2021
View articletitled, Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody–Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non–Small Cell Lung Carcinoma
Open the PDF for Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody–Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non–Small Cell Lung Carcinoma in another window
Includes: Supplementary data
Journal Articles

Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53

Mansoor N. Saleh, Manish R. Patel, Todd M. Bauer, Sanjay Goel, Gerald S. Falchook, Geoffrey I. Shapiro, Ki Y. Chung, Jeffrey R. Infante, Robert M. Conry, Guilherme Rabinowits, David S. Hong, Judy S. Wang, Ulrich Steidl, Gurudatta Naik, Vincent Guerlavais, Vojislav Vukovic, D. Allen Annis, Manuel Aivado, Funda Meric-Bernstam
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (19): 5236–5247.
https://doi.org/10.1158/1078-0432.CCR-21-0715
Published: 01 October 2021
View articletitled, Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53
Open the PDF for Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53 in another window
Includes: Supplementary data
Journal Articles

Tropomyosin Receptor Kinase Inhibitors for the Treatment of TRK Fusion Cancer

Theodore W. Laetsch, David S. Hong
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (18): 4974–4982.
https://doi.org/10.1158/1078-0432.CCR-21-0465
Published: 15 September 2021
View articletitled, Tropomyosin Receptor Kinase Inhibitors for the Treatment of TRK Fusion Cancer
Open the PDF for Tropomyosin Receptor Kinase Inhibitors for the Treatment of TRK Fusion Cancer in another window
Journal Articles

A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies

Aparna Hegde, Priyamvada Jayaprakash, Coline A. Couillault, Sarina Piha-Paul, Daniel Karp, Jordi Rodon, Shubham Pant, Siqing Fu, Ecaterina E. Dumbrava, Timothy A. Yap, Vivek Subbiah, Priya Bhosale, Cristian Coarfa, Jack P. Higgins, Eric T. Williams, Thomas F. Wilson, JoAnn Lim, Funda Meric-Bernstam, Elizabeth Sumner, Hira Zain, Di Nguyen, Ly M. Nguyen, Kimal Rajapakshe, Michael A. Curran, David S. Hong
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (11): 3050–3060.
https://doi.org/10.1158/1078-0432.CCR-20-4118
Published: 01 June 2021
View articletitled, A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies
Open the PDF for A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies in another window
Includes: Supplementary data
Journal Articles

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO–Friends of Cancer Research Prior Therapies Work Group

Raymond U. Osarogiagbon, Diana Merino Vega, Lola Fashoyin-Aje, Suparna Wedam, Gwynn Ison, Sol Atienza, Peter De Porre, Tithi Biswas, Jamie N. Holloway, David S. Hong, Madison M. Wempe, Richard L. Schilsky, Edward S. Kim, James L. Wade, III
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (9): 2408–2415.
https://doi.org/10.1158/1078-0432.CCR-20-3854
Published: 01 May 2021
View articletitled, Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO–Friends of Cancer Research Prior Therapies Work Group
Open the PDF for Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO–Friends of Cancer Research Prior Therapies Work Group in another window
Journal Articles

Preclinical Evaluation and Phase Ib Study of Prexasertib, a CHK1 Inhibitor, and Samotolisib (LY3023414), a Dual PI3K/mTOR Inhibitor

David S. Hong, Kathleen N. Moore, Johanna C. Bendell, Daniel D. Karp, Judy S. Wang, Susanna V. Ulahannan, Suzanne Jones, Wenjuan Wu, Gregory P. Donoho, Yan Ding, Andrew Capen, Xuejing Wang, Aimee Bence Lin, Manish R. Patel
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (7): 1864–1874.
https://doi.org/10.1158/1078-0432.CCR-20-3242
Published: 01 April 2021
View articletitled, Preclinical Evaluation and Phase Ib Study of Prexasertib, a CHK1 Inhibitor, and Samotolisib (LY3023414), a Dual PI3K/mTOR Inhibitor
Open the PDF for Preclinical Evaluation and Phase Ib Study of Prexasertib, a CHK1 Inhibitor, and Samotolisib (LY3023414), a Dual PI3K/mTOR Inhibitor in another window
Includes: Supplementary data
Journal Articles

Phase I Study of Everolimus, Letrozole, and Trastuzumab in Patients with Hormone Receptor−positive Metastatic Breast Cancer or Other Solid Tumors

Alexej Ballhausen, Jennifer J. Wheler, Daniel D. Karp, Sarina A. Piha-Paul, Siqing Fu, Shubham Pant, Apostolia M. Tsimberidou, David S. Hong, Vivek Subbiah, Veronica R. Holley, Helen J. Huang, Abenaa M. Brewster, Kimberly B. Koenig, Nuhad K. Ibrahim, Funda Meric-Bernstam, Filip Janku
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (5): 1247–1255.
https://doi.org/10.1158/1078-0432.CCR-20-2878
Published: 01 March 2021
View articletitled, Phase I Study of Everolimus, Letrozole, and Trastuzumab in Patients with Hormone Receptor−positive Metastatic Breast Cancer or Other Solid Tumors
Open the PDF for Phase I Study of Everolimus, Letrozole, and Trastuzumab in Patients with Hormone Receptor−positive Metastatic Breast Cancer or Other Solid Tumors in another window
Journal Articles

Intratumoral Injection of Clostridium novyi-NT Spores in Patients with Treatment-refractory Advanced Solid Tumors

Filip Janku, Halle Huihong Zhang, Abdulmohammad Pezeshki, Sanjay Goel, Ravi Murthy, Andrea Wang-Gillam, Dale R. Shepard, Thorunn Helgason, Tyler Masters, David S. Hong, Sarina A. Piha-Paul, Daniel D. Karp, Mark Klang, Steven Y. Huang, Divya Sakamuri, Anjali Raina, Jean Torrisi, Stephen B. Solomon, Alice Weissfeld, Ernest Trevino, Gary DeCrescenzo, Amanda Collins, Maria Miller, Jennifer L. Salstrom, Ronald L. Korn, Linping Zhang, Saurabh Saha, Alexey A. Leontovich, David Tung, Brent Kreider, Mary Varterasian, Khashayarsha Khazaie, Mrinal M. Gounder
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (1): 96–106.
https://doi.org/10.1158/1078-0432.CCR-20-2065
Published: 04 January 2021
View articletitled, Intratumoral Injection of Clostridium novyi-NT Spores in Patients with Treatment-refractory Advanced Solid Tumors
Open the PDF for Intratumoral Injection of Clostridium novyi-NT Spores in Patients with Treatment-refractory Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Phase I Study of P-cadherin–targeted Radioimmunotherapy with 90Y-FF-21101 Monoclonal Antibody in Solid Tumors

Vivek Subbiah, William Erwin, Osama Mawlawi, Asa McCoy, David Wages, Catherine Wheeler, Carlos Gonzalez-Lepera, Holly Liu, Homer Macapinlac, Funda Meric-Bernstam, David S. Hong, Shubham Pant, Dao Le, Elmer Santos, Jose Gonzalez, Jason Roszik, Takeaki Suzuki, Ruth Ann Subach, Timothy Madden, Mary Johansen, Fumiko Nomura, Hirokazu Satoh, Tadashi Matsuura, Masamichi Kajita, Eri Nakamura, Yuichi Funase, Satoshi Matsushima, Gregory Ravizzini
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (22): 5830–5842.
https://doi.org/10.1158/1078-0432.CCR-20-0037
Published: 13 November 2020
View articletitled, Phase I Study of P-cadherin–targeted Radioimmunotherapy with 90Y-FF-21101 Monoclonal Antibody in Solid Tumors
Open the PDF for Phase I Study of P-cadherin–targeted Radioimmunotherapy with 90Y-FF-21101 Monoclonal Antibody in Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma

Filip Janku, Haeseong Park, S. Greg Call, Kiran Madwani, Yasuhiro Oki, Vivek Subbiah, David S. Hong, Aung Naing, Vivianne M. Velez-Bravo, Tamara G. Barnes, Fredrick B. Hagemeister, Gerald S. Falchook, Daniel D. Karp, Jennifer J. Wheler, Sarina A. Piha-Paul, Ignacio Garrido-Laguna, Elizabeth J. Shpall, Luis E. Fayad, Sattva S. Neelapu, Funda Meric-Bernstam, Razelle Kurzrock, Michelle A. Fanale
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (21): 5579–5587.
https://doi.org/10.1158/1078-0432.CCR-20-1215
Published: 02 November 2020
View articletitled, Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma
Open the PDF for Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma in another window
Includes: Supplementary data
Journal Articles

Mogamulizumab in Combination with Durvalumab or Tremelimumab in Patients with Advanced Solid Tumors: A Phase I Study

Dmitriy Zamarin, Omid Hamid, Asha Nayak-Kapoor, Solmaz Sahebjam, Mario Sznol, Agron Collaku, Floyd E. Fox, Margaret A. Marshall, David S. Hong
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (17): 4531–4541.
https://doi.org/10.1158/1078-0432.CCR-20-0328
Published: 01 September 2020
View articletitled, Mogamulizumab in Combination with Durvalumab or Tremelimumab in Patients with Advanced Solid Tumors: A Phase I Study
Open the PDF for Mogamulizumab in Combination with Durvalumab or Tremelimumab in Patients with Advanced Solid Tumors: A Phase I Study in another window
Includes: Supplementary data
Journal Articles

Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer

Seyed Pairawan, Kenneth R. Hess, Filip Janku, Nora S. Sanchez, Kenna R. Mills Shaw, Cathy Eng, Senthilkumar Damodaran, Milind Javle, Ahmed O. Kaseb, David S. Hong, Vivek Subbiah, Siqing Fu, David R. Fogelman, Victoria M. Raymond, Richard B. Lanman, Funda Meric-Bernstam
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (8): 1924–1931.
https://doi.org/10.1158/1078-0432.CCR-19-0306
Published: 15 April 2020
View articletitled, Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer
Open the PDF for Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer in another window
Includes: Supplementary data
Journal Articles

First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors

Gerald S. Falchook, Razelle Kurzrock, Hesham M. Amin, Wenyuan Xiong, Siqing Fu, Sarina A. Piha-Paul, Filip Janku, Ghazaleh Eskandari, Daniel V. Catenacci, Manfred Klevesath, Rolf Bruns, Uz Stammberger, Andreas Johne, Friedhelm Bladt, Manja Friese-Hamim, Pascal Girard, Samer El Bawab, David S. Hong
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (6): 1237–1246.
https://doi.org/10.1158/1078-0432.CCR-19-2860
Published: 13 March 2020
View articletitled, First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors
Open the PDF for First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data